FY2025 Earnings Estimate for LEXX Issued By Zacks Small Cap

Lexaria Bioscience Corp. (NASDAQ:LEXX) – Investment analysts at Zacks Small Cap decreased their FY2025 earnings per share estimates for Lexaria Bioscience in a research report issued on Thursday, April 24th. Zacks Small Cap analyst J. Vandermosten now expects that the company will post earnings per share of ($0.58) for the year, down from their prior estimate of ($0.57). The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.59) per share.

Lexaria Bioscience (NASDAQ:LEXX) last announced its earnings results on Monday, April 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. The firm had revenue of $0.17 million during the quarter, compared to analyst estimates of $0.14 million. Lexaria Bioscience had a negative net margin of 1,473.04% and a negative return on equity of 88.88%.

Separately, HC Wainwright decreased their price target on Lexaria Bioscience from $10.00 to $7.00 and set a “buy” rating for the company in a research note on Friday, January 24th.

Lexaria Bioscience Price Performance

NASDAQ LEXX opened at $1.17 on Monday. Lexaria Bioscience has a 12 month low of $1.15 and a 12 month high of $4.44. The firm has a market capitalization of $20.54 million, a PE ratio of -2.34 and a beta of 0.86. The company’s 50 day simple moving average is $1.47 and its 200 day simple moving average is $1.92.

Institutional Investors Weigh In On Lexaria Bioscience

Several hedge funds and other institutional investors have recently bought and sold shares of LEXX. Byrne Asset Management LLC grew its stake in shares of Lexaria Bioscience by 132.1% in the 4th quarter. Byrne Asset Management LLC now owns 13,000 shares of the company’s stock worth $27,000 after purchasing an additional 7,400 shares during the last quarter. HighTower Advisors LLC boosted its holdings in Lexaria Bioscience by 61.4% during the fourth quarter. HighTower Advisors LLC now owns 21,023 shares of the company’s stock worth $44,000 after buying an additional 8,000 shares in the last quarter. Wealth Enhancement Advisory Services LLC grew its position in Lexaria Bioscience by 108.9% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 28,873 shares of the company’s stock worth $61,000 after buying an additional 15,050 shares during the last quarter. Raymond James Financial Inc. bought a new position in shares of Lexaria Bioscience in the fourth quarter valued at $127,000. Finally, Geode Capital Management LLC lifted its position in shares of Lexaria Bioscience by 10.8% during the 4th quarter. Geode Capital Management LLC now owns 166,679 shares of the company’s stock valued at $350,000 after acquiring an additional 16,288 shares during the last quarter. 13.06% of the stock is currently owned by institutional investors.

Lexaria Bioscience Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods.